Home > Journals > Minerva Pediatrics > Past Issues > Minerva Pediatrics 2021 December;73(6) > Minerva Pediatrics 2021 December;73(6):486-503

CURRENT ISSUE
 

JOURNAL TOOLS

Publishing options
eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

REVIEW  UPDATE IN PEDIATRIC DIABETES AND ENDOCRINOLOGY: PROCEEDING OF THE 7TH WINTER AND SUMMER ISPED SCHOOL FOR PHYSICIANS 

Minerva Pediatrics 2021 December;73(6):486-503

DOI: 10.23736/S2724-5276.21.06529-0

Copyright © 2021 EDIZIONI MINERVA MEDICA

language: English

Prevention of type 1 diabetes: where we are and where we are going

Giulio FRONTINO 1, Salvatore GUERCIO NUZIO 2, Andrea SCARAMUZZA 3, Giuseppe D’ANNUNZIO 4, Sonia TONI 5, Felice CITRINITI 6, Riccardo BONFANTI 7

1 Department of Pediatrics, Diabetes Research Institute, IRCCS San Raffaele Hospital, Milan, Italy; 2 Division of Pediatrics, Santa Maria della Speranza Hospital, ASL Salerno, Battipaglia, Salerno, Italy; 3 Division of Pediatrics, Maggiore Hospital, ASST Cremona, Cremona, Italy; 4 Unit of Endocrinology, Clinic of Pediatrics, IRCCS Istituto Giannina Gaslini, Genoa, Italy; 5 Unit of Diabetology and Endocrinology, Meyer Children Hospital, Florence, Italy; 6 Department of Pediatrics, Pugliese-Ciaccio Hospital, Catanzaro, Italy; 7 Unit of Pediatric Diabetes, Department of Pediatrics, Diabetes Research Institute, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy



T1D (T1D) is one of the most frequent chronic disease in children and is associated to the risk of severe acute and chronic complications. There are about 550,000 children with T1D in the world; and about 86,000 children are diagnosed with T1D every year and its incidence is ever increasing. In this narrative review we will discuss current and future perspectives in T1D prevention strategies as well as their pitfalls. It is important to remember that for the first time one drug, in particular teplizumab (antibody anti-CD3) is going to be accepted for treatment in stage 2 of type 1 diabetes mellitus. This represent the onset of a new era.


KEY WORDS: Diabetes Mellitus, type 1; Prevention and control; Pediatrics

top of page